[Form 4] MetLife, Inc. Insider Trading Activity
MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.
Il direttore Jeh C. Johnson di MetLife, Inc. (MET), ha comunicato una piccola acquisizione non derivativa di azioni della società. Il modulo 4 mostra un reinvestimento imputato dei dividendi nell’ambito del MetLife Deferred Compensation Plan for Non-Management Directors, risultando in una acquisizione di 48 azioni il 09/09/2025 a un prezzo imputato di 79,29 USD per azione. A seguito della transazione, la persona che segnala deteneva 6.838 azioni. La pratica è stata firmata da un procuratore-in-fatto il 11/09/2025. La comunicazione riflette un reinvestimento ordinario dei dividendi piuttosto che un acquisto sul mercato aperto o l’esercizio di opzioni.
El director Jeh C. Johnson de MetLife, Inc. (MET) reportó una pequeña adquisición no derivativa de acciones de la empresa. El Formulario 4 muestra un reinversión imputada de dividendos bajo el MetLife Deferred Compensation Plan for Non-Management Directors, resultando en la adquisición de 48 acciones el 09/09/2025 a un precio imputado de $79.29 por acción. Tras la transacción, la persona que presenta el informe poseía 6,838 acciones. El documento fue firmado por un apoderado en calidad de mandatario el 11/09/2025. La divulgación refleja un reinversión de dividendos rutinario en lugar de una compra en el mercado abierto o el ejercicio de opciones.
MetLife, Inc.의 이사 Jeh C. Johnson이 회사 주식의 소액 비파생적 매수를 보고했습니다. Form 4는 비경영 이사를 위한 MetLife Deferred Compensation Plan 하에서 배당금의 내재적 재투자를 보여 주며, 2025년 9월 9일 주당 79.29달러의 내재 가격으로 48주를 취득하게 되었습니다. 거래 후 보고자은 6,838주를 보유하게 되었습니다. 제출은 2025년 9월 11일 대리인이 서명했습니다. 공시는 일반적인 배당 재투자를 반영하며, 공개시장의 매수나 옵션 행사가 아님을 나타냅니다.
Le directeur Jeh C. Johnson de MetLife, Inc. (MET) a signalé une petite acquisition non dérivée d’actions de la société. Le formulaire 4 montre une réintégration imputée de dividendes dans le cadre du MetLife Deferred Compensation Plan for Non-Management Directors, entraînant l’acquisition de 48 actions le 09/09/2025 à un prix imputé de 79,29 USD par action. Suite à la transaction, la personne déclarant détenait 6 838 actions. Le dépôt a été signé par un mandataire le 11/09/2025. La divulgation reflète une réinvestissement courant des dividendes plutôt qu’un achat sur le marché libre ou l’exercice d’options.
Der MetLife-Direktor Jeh C. Johnson (MET) meldete einen kleinen nicht abgeleiteten Erwerb von Unternehmensaktien. Das Formular 4 zeigt eine imputierte Dividendenreinvestition im Rahmen des MetLife Deferred Compensation Plan for Non-Management Directors, wodurch am 09.09.2025 der Erwerb von 48 Aktien zu einem imputierten Preis von 79,29 USD pro Aktie erfolgte. Nach der Transaktion besaß die meldende Person 6.838 Aktien. Die Einreichung wurde von einem Prokuristen am 11.09.2025 unterzeichnet. Die Offenlegung spiegelt eine routinemäßige Dividendenreinvestition wider und nicht einen Kauf am offenen Markt oder die Ausübung von Optionen.
أبلغ المدير لدى MetLife، Inc. (MET) السيد جيه سي جونسون عن الحصول على كمية صغيرة من أسهم الشركة عن طريق غير مشتقة. يظهر النموذج 4 إعادة استثمار افتراضي للأرباح بموجب خطة MetLife Deferred Compensation Plan for Non-Management Directors، مما يوصل إلى اكتساب 48 سهماً في 09/09/2025 بسعر افتراضي قدره 79.29 دولاراً للسهم. وبعد الصفقة، امتلك الشخص المبلغ تقريراً 6,838 سهماً. تم توقيع الإبلاغ من قبل ممثل قانوني في 11/09/2025. يعكس الإفصاح إعادة استثمار روتينية للأرباح بدلاً من شراء السوق المفتوحة أو ممارسة الخيارات.
MetLife, Inc.(MET)董事 Jeh C. Johnson 报告了对公司股票的少量非衍生性买入。 第4表显示在 MetLife Deferred Compensation Plan for Non-Management Directors 下的股息自动再投资,导致在 2025-09-09 以每股 79.29 美元的隐含价格买入 48 股。交易后,申报人实际拥有 6,838 股。该 filing 由代理律师于 2025-09-11 签署。披露显示为常规的股息再投资,而非在公开市场的买入或行使期权。
- Increased insider ownership: Reporting person beneficially owns 6,838 shares after the reinvestment, modestly increasing alignment with shareholders
- Proper disclosure: Transaction reported on Form 4 and signed by attorney-in-fact, demonstrating compliance with Section 16 reporting requirements
- None.
Insights
Routine dividend reinvestment; immaterial to valuation but increases insider stake modestly.
The reported 48-share acquisition is the result of dividend reinvestment under the company plan, not an active market trade. At $79.29 implied price, the transaction increases the director's direct holdings to 6,838 shares, a small change relative to typical institutional positions. There are no derivative exercises, sales, or other actions that would signal a change in insider sentiment or corporate control.
Disclosure meets Section 16 reporting standards; transaction appears procedural and non-material.
The Form 4 documents an imputed dividend reinvestment under the deferred compensation plan for non-management directors. Signature by an attorney-in-fact is noted. The filing aligns with standard insider reporting obligations and does not indicate any governance or compliance issues based on the provided information.
Il direttore Jeh C. Johnson di MetLife, Inc. (MET), ha comunicato una piccola acquisizione non derivativa di azioni della società. Il modulo 4 mostra un reinvestimento imputato dei dividendi nell’ambito del MetLife Deferred Compensation Plan for Non-Management Directors, risultando in una acquisizione di 48 azioni il 09/09/2025 a un prezzo imputato di 79,29 USD per azione. A seguito della transazione, la persona che segnala deteneva 6.838 azioni. La pratica è stata firmata da un procuratore-in-fatto il 11/09/2025. La comunicazione riflette un reinvestimento ordinario dei dividendi piuttosto che un acquisto sul mercato aperto o l’esercizio di opzioni.
El director Jeh C. Johnson de MetLife, Inc. (MET) reportó una pequeña adquisición no derivativa de acciones de la empresa. El Formulario 4 muestra un reinversión imputada de dividendos bajo el MetLife Deferred Compensation Plan for Non-Management Directors, resultando en la adquisición de 48 acciones el 09/09/2025 a un precio imputado de $79.29 por acción. Tras la transacción, la persona que presenta el informe poseía 6,838 acciones. El documento fue firmado por un apoderado en calidad de mandatario el 11/09/2025. La divulgación refleja un reinversión de dividendos rutinario en lugar de una compra en el mercado abierto o el ejercicio de opciones.
MetLife, Inc.의 이사 Jeh C. Johnson이 회사 주식의 소액 비파생적 매수를 보고했습니다. Form 4는 비경영 이사를 위한 MetLife Deferred Compensation Plan 하에서 배당금의 내재적 재투자를 보여 주며, 2025년 9월 9일 주당 79.29달러의 내재 가격으로 48주를 취득하게 되었습니다. 거래 후 보고자은 6,838주를 보유하게 되었습니다. 제출은 2025년 9월 11일 대리인이 서명했습니다. 공시는 일반적인 배당 재투자를 반영하며, 공개시장의 매수나 옵션 행사가 아님을 나타냅니다.
Le directeur Jeh C. Johnson de MetLife, Inc. (MET) a signalé une petite acquisition non dérivée d’actions de la société. Le formulaire 4 montre une réintégration imputée de dividendes dans le cadre du MetLife Deferred Compensation Plan for Non-Management Directors, entraînant l’acquisition de 48 actions le 09/09/2025 à un prix imputé de 79,29 USD par action. Suite à la transaction, la personne déclarant détenait 6 838 actions. Le dépôt a été signé par un mandataire le 11/09/2025. La divulgation reflète une réinvestissement courant des dividendes plutôt qu’un achat sur le marché libre ou l’exercice d’options.
Der MetLife-Direktor Jeh C. Johnson (MET) meldete einen kleinen nicht abgeleiteten Erwerb von Unternehmensaktien. Das Formular 4 zeigt eine imputierte Dividendenreinvestition im Rahmen des MetLife Deferred Compensation Plan for Non-Management Directors, wodurch am 09.09.2025 der Erwerb von 48 Aktien zu einem imputierten Preis von 79,29 USD pro Aktie erfolgte. Nach der Transaktion besaß die meldende Person 6.838 Aktien. Die Einreichung wurde von einem Prokuristen am 11.09.2025 unterzeichnet. Die Offenlegung spiegelt eine routinemäßige Dividendenreinvestition wider und nicht einen Kauf am offenen Markt oder die Ausübung von Optionen.